Transfemoral Versus Transradial Approach in Transarterial Chemoembolization of Hepatocellular Carcinoma
NCT ID: NCT06543030
Last Updated: 2024-08-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
60 participants
OBSERVATIONAL
2024-08-31
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trans-arterial Chemoembolization in Patients With Hepatocellular Carcinoma: A Study of Different Outcomes and Their Predictive Factors
NCT04739501
Single Session Combined Locoregional Therapies for Hepatocellular Carcinoma
NCT02646137
Different Regimens of Transarterial Chemoembolization for Hepatocellular Carcinoma
NCT00493402
Different Protocols for Repeated Transarterial Chemoembolization in the Treatment of Patients With Hepatocellular Carcinoma
NCT02038296
Efficacy of Loco-regional Treatment for Hepatocellular Carcinoma Prior to Living Donor Liver Transplantation in Egypt
NCT02990351
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Transfemoral approach (TFA) group
No interventions assigned to this group
Transradial approach (TRA) group
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Also for BCLC stage A patients, in whom ablative therapy has technical limitations.
* Downsizing tumor for resection or transplantation.
Exclusion Criteria
* Decompensated cirrhosis (Child-Pugh B and C, score \>8), including jaundice, clinical hepatic encephalopathy, and refractory ascites and/ or hepatorenal syndrome
* Impaired portal-vein blood flow (portal-vein thrombus, hepatofugal blood flow)
* Factors related to HCC:
* Extensive tumor involving the entirety of both lobes of the liver
* Malignant portal vein thrombosis
* Extra-hepatic metastases
* Impaired renal function:
* Creatinine ≥2 mg/dl or creatinine clearance \<30 ml/min
* Factors related to procedure (Radial artery access):
* Existing AV (arteriovenous) fistula or graft
* Pervious major surgery to forearm or wrist
* Vasculitis
* Pervious access failure
* Skin infection or compromised integrity
* Artery size \<2mm
* Intolerance of hyperextended wrist positioning
* Severe vasospasm
* Vessel tortuosity
* Radial loops
* Absent or occluded radial artery
* Atherosclerotic or calcific PAD (peripheral artery disease)
* Coagulopathy INR\>1.5 platelets count \<50.000/mmc
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ali Adel Abouelmagd Sewisy
M.B.B.CH at Radiology department of Assuit university
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assiut University hospitals
Asyut, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TACE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.